Loading stock data…
Aardvark Therapeutics (AARD)
$5.33-0.05 (-0.93%)
After Hours$5.33+0.00 (+0.00%)· Last close Sep 8
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aardvark Therapeutics, Inc. in the Healthcare sector is trading at $5.33 with a market capitalization of $84M. Wall Street consensus targets $11.11 (9 analysts), implying a +108.5% move over the next 12 months. The stock is currently near its 52-week low of $3.35, remaining 32.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +108.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$22.46M↓ | -$18.70M↓ | -$17.70M↓ | -$15.85M↓ | -$10.47M |
| Net Income | -$21.59M↓ | -$17.60M↓ | -$16.32M↓ | -$14.37M↓ | -$9.31M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$83.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-80.32%
Volume
Today's trading volume
164,744
Recent News
Aardvark Therapeutics Inc (AARD) (Q2 2026) Earnings Call Highlights: Board Re-Elected, Auditor ...
Procedural meeting confirms leadership continuity and financial oversight, but offers no new strategic or operational insights for investors.
Several Insiders Invested In Aardvark Therapeutics Flagging Positive News
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.1% and
Top Midday Decliners
LanzaTech Global (LNZA) signed a securities purchase agreement with certain institutional investors
FDA hold puts Aardvark Prader-Willi drug in limbo
The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.